Yhn HealthMental Health first seen 3 d ago, last 1 h ago, peak #1
One-Shot CRISPR Therapies Targeting PCSK9 Gain Attention
Original: In-Vivo CRISPR/Base-Editing "One-Shot" Therapies Targeting PCSK9
A new review in Current Atherosclerosis Reports examines in-vivo CRISPR and base-editing 'one-shot' therapies that target PCSK9, a gene that regulates cholesterol levels. The approach aims to permanently lower LDL cholesterol with a single infusion, potentially replacing daily statins for some patients. Early trials of similar editing therapies have shown durable cholesterol reductions, and discussion is focused on how close these treatments are to clinical use.
Why now: A newly published review on one-time gene-editing treatments for high cholesterol has drawn attention to a potential alternative to lifelong medication.
PCSK9CRISPRSpringerCurrent Atherosclerosis Reports
Rank over time, top of the chart is #1. 66 snapshots from 3 d ago to 1 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3255814